These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 26690825)

  • 1. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
    Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
    Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer.
    Guiu B; Petit JM; Bonnetain F; Ladoire S; Guiu S; Cercueil JP; Krausé D; Hillon P; Borg C; Chauffert B; Ghiringhelli F
    Gut; 2010 Mar; 59(3):341-7. PubMed ID: 19837679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
    Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
    Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Impact of Abdominal Fat Distribution on Prognosis After Esophagectomy for Esophageal Squamous Cell Carcinoma.
    Okamura A; Watanabe M; Mine S; Nishida K; Imamura Y; Kurogochi T; Kitagawa Y; Sano T
    Ann Surg Oncol; 2016 Apr; 23(4):1387-94. PubMed ID: 26668084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of abdominal fat distribution and inflammatory status on post-operative prognosis in non-small cell lung cancer patients: a retrospective cohort study.
    Ma M; Luo M; Liu Q; Zhong D; Liu Y; Zhang K
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):111. PubMed ID: 38431748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
    Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
    Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.
    Ladoire S; Bonnetain F; Gauthier M; Zanetta S; Petit JM; Guiu S; Kermarrec I; Mourey E; Michel F; Krause D; Hillon P; Cormier L; Ghiringhelli F; Guiu B
    Oncologist; 2011; 16(1):71-81. PubMed ID: 21212435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body Fatness, Adipose Tissue Compartments, and Biomarkers of Inflammation and Angiogenesis in Colorectal Cancer: The ColoCare Study.
    Himbert C; Ose J; Nattenmüller J; Warby CA; Holowatyj AN; Böhm J; Lin T; Haffa M; Gigic B; Hardikar S; Scherer D; Zielske L; Schrotz-King P; Kölsch T; Siegel EM; Shibata D; Ulrich A; Schneider M; Hursting SD; Kauczor HU; Ulrich CM
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):76-82. PubMed ID: 30333223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
    Miyamoto Y; Oki E; Emi Y; Tokunaga S; Shimokawa M; Ogata Y; Akagi Y; Sakamoto Y; Tanaka T; Saeki H; Maehara Y; Baba H
    Anticancer Res; 2018 Jan; 38(1):491-499. PubMed ID: 29277814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visceral fat area and subcutaneous fat area as measures of body composition in soft tissue sarcoma.
    Garibay ER; Cruz SM; Judge SJ; Monjazeb AM; Thorpe SW; Murphy WJ; Lyu J; Chen S; Bateni CP; Canter RJ
    J Surg Oncol; 2024 Sep; 130(3):543-551. PubMed ID: 39402905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visceral obesity is associated with outcomes of total mesorectal excision for rectal adenocarcinoma.
    Ballian N; Lubner MG; Munoz A; Harms BA; Heise CP; Foley EF; Kennedy GD
    J Surg Oncol; 2012 Mar; 105(4):365-70. PubMed ID: 21751219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
    Betge J; Barat A; Murphy V; Hielscher T; Van Grieken NC; Belle S; Zhan T; Härtel N; Kripp M; Bacon O; Cordes M; Kay EW; Verheul HM; Neerincx M; Hennessy B; Hofheinz RD; Gaiser T; Ylstra B; Prehn JH; Lambrechts D; Byrne AT; Ebert MP; Schulte N
    Digestion; 2016; 94(3):129-137. PubMed ID: 27756074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Overall Survival in Patients With Metastatic Melanoma on Antiangiogenic Therapy and RECIST Stable Disease on Initial Posttherapy Images Using CT Texture Analysis.
    Smith AD; Gray MR; del Campo SM; Shlapak D; Ganeshan B; Zhang X; Carson WE
    AJR Am J Roentgenol; 2015 Sep; 205(3):W283-93. PubMed ID: 26295664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Computed Tomography-based Abdominal Adiposity Indexes as Predictors of Non-alcoholic Fatty Liver Disease Among Middle-aged Korean Men and Women.
    Baek J; Jung SJ; Shim JS; Jeon YW; Seo E; Kim HC
    J Prev Med Public Health; 2020 Jul; 53(4):256-265. PubMed ID: 32752595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Abdominal Fat Levels on All-Cause Mortality Risk in Patients Undergoing Hemodialysis.
    Yajima T; Yajima K; Takahashi H; Yasuda K
    Nutrients; 2018 Apr; 10(4):. PubMed ID: 29649164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis.
    Esposito A; Marra A; Bagnardi V; Frassoni S; Morganti S; Viale G; Zagami P; Varano GM; Buccimazza G; Orsi F; Venetis K; Mazzarella L; Viale G; Fusco N; Criscitiello C; Curigliano G
    Eur J Cancer; 2021 Mar; 145():197-209. PubMed ID: 33493979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer.
    Cazeneuve N; Bouché O; Leger J; Borg C; Labbe-Devilliers C; Lucidarme O; Tasu JP; Manfredi S; Aubé C; Trillaud H; Manzoni P; Marcus C; Terrebonne E; Douillard JY; Chautard R; Lobet S; Scotto B; Bleuzen A; Lecomte T
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102380. PubMed ID: 38788975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High visceral fat with low subcutaneous fat accumulation as a determinant of atherosclerosis in patients with type 2 diabetes.
    Bouchi R; Takeuchi T; Akihisa M; Ohara N; Nakano Y; Nishitani R; Murakami M; Fukuda T; Fujita M; Minami I; Izumiyama H; Hashimoto K; Yoshimoto T; Ogawa Y
    Cardiovasc Diabetol; 2015 Oct; 14():136. PubMed ID: 26445876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.
    Chinot OL; Nishikawa R; Mason W; Henriksson R; Saran F; Cloughesy T; Garcia J; Revil C; Abrey L; Wick W
    Neuro Oncol; 2016 Sep; 18(9):1313-8. PubMed ID: 27006178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body fat distribution is more predictive of all-cause mortality than overall adiposity.
    Lee SW; Son JY; Kim JM; Hwang SS; Han JS; Heo NJ
    Diabetes Obes Metab; 2018 Jan; 20(1):141-147. PubMed ID: 28671751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.